# Sangamo Therapeutics, Inc: financial statements, quarterly

SGMOQ · OTC · CIK 1001233 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sgmoq.md) · [Financials](/companies/sgmoq/financials.md) · [Filings](/companies/sgmoq/filings.md) · [Insiders](/companies/sgmoq/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sgmoq/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.8](/filings/0001628280-24-035165.md) | [9.4](/filings/0001628280-24-047102.md) | [2.0 d](/filings/0001628280-25-013088.md) | [0.5](/filings/0001628280-25-024650.md) | [0.4](/filings/0001628280-25-038860.md) | [49.4](/filings/0001001233-25-000024.md) | [7.6 d](/filings/0001628280-26-022029.md) | [6.4](/filings/0001628280-26-035067.md) | [18.3](/filings/0001628280-25-038860.md) | [0.6](/filings/0001001233-25-000024.md) | [14.2 d](/filings/0001628280-26-022029.md) | [1.4](/filings/0001628280-26-035067.md) |
| Research and development | $m | [63.0](/filings/0001628280-24-035165.md) | [57.1](/filings/0001628280-24-047102.md) | [50.7 d](/filings/0001628280-25-013088.md) | [35.9](/filings/0001628280-25-024650.md) | [24.2](/filings/0001628280-25-038860.md) | [27.7](/filings/0001001233-25-000024.md) | [23.7 d](/filings/0001628280-26-022029.md) | [26.0](/filings/0001628280-26-035067.md) | [27.1](/filings/0001628280-25-038860.md) | [28.1](/filings/0001001233-25-000024.md) | [31.4 d](/filings/0001628280-26-022029.md) | [26.6](/filings/0001628280-26-035067.md) |
| Operating income | $m | [(124)](/filings/0001628280-24-035165.md) | [(106)](/filings/0001628280-24-047102.md) | [(62.1) d](/filings/0001628280-25-013088.md) | [(51.5)](/filings/0001628280-25-024650.md) | [(37.1)](/filings/0001628280-25-038860.md) | [10.6](/filings/0001001233-25-000024.md) | [(26.0) d](/filings/0001628280-26-022029.md) | [(29.6)](/filings/0001628280-26-035067.md) | [(17.9)](/filings/0001628280-25-038860.md) | [(35.6)](/filings/0001001233-25-000024.md) | [(38.2) d](/filings/0001628280-26-022029.md) | [(31.9)](/filings/0001628280-26-035067.md) |
| Income tax | $m | [(6.3)](/filings/0001628280-24-035165.md) | [1.3](/filings/0001628280-24-047102.md) | [(0.3) d](/filings/0001628280-25-013088.md) | [0.1](/filings/0001628280-25-024650.md) | [0.1](/filings/0001628280-25-038860.md) | [0.1](/filings/0001001233-25-000024.md) | [(0.4) d](/filings/0001628280-26-022029.md) | [0.1](/filings/0001628280-26-035067.md) | [0.0](/filings/0001628280-25-038860.md) | [(0.2)](/filings/0001001233-25-000024.md) | [(0.6) d](/filings/0001628280-26-022029.md) | [0.0](/filings/0001628280-26-035067.md) |
| Net income | $m | [(115)](/filings/0001628280-24-035165.md) | [(104)](/filings/0001628280-24-047102.md) | [(60.3) d](/filings/0001628280-25-013088.md) | [(49.1)](/filings/0001628280-25-024650.md) | [(36.1)](/filings/0001628280-25-038860.md) | [10.7](/filings/0001001233-25-000024.md) | [(23.4) d](/filings/0001628280-26-022029.md) | [(30.6)](/filings/0001628280-26-035067.md) | [(20.0)](/filings/0001628280-25-038860.md) | [(34.9)](/filings/0001001233-25-000024.md) | [(37.4) d](/filings/0001628280-26-022029.md) | [(31.0)](/filings/0001628280-26-035067.md) |
| Diluted EPS | $ per share | [(0.66)](/filings/0001628280-24-035165.md) | [(0.59)](/filings/0001628280-24-047102.md) | not reported | [(0.27)](/filings/0001628280-25-024650.md) | [(0.18)](/filings/0001628280-25-038860.md) | [0.04](/filings/0001001233-25-000024.md) | not reported | [(0.14)](/filings/0001628280-26-035067.md) | [(0.08)](/filings/0001628280-25-038860.md) | [(0.11)](/filings/0001001233-25-000024.md) | not reported | [(0.08)](/filings/0001628280-26-035067.md) |
| Basic EPS | $ per share | [(0.66)](/filings/0001628280-24-035165.md) | [(0.59)](/filings/0001628280-24-047102.md) | not reported | [(0.27)](/filings/0001628280-25-024650.md) | [(0.18)](/filings/0001628280-25-038860.md) | [0.05](/filings/0001001233-25-000024.md) | not reported | [(0.14)](/filings/0001628280-26-035067.md) | [(0.08)](/filings/0001628280-25-038860.md) | [(0.11)](/filings/0001001233-25-000024.md) | not reported | [(0.08)](/filings/0001628280-26-035067.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [66.8](/filings/0001628280-24-035165.md) | [56.5](/filings/0001628280-24-047102.md) | [45.2](/filings/0001001233-25-000024.md) | [54.4](/filings/0001628280-25-024650.md) | [27.8](/filings/0001628280-25-038860.md) | [39.2](/filings/0001001233-25-000024.md) | [41.9](/filings/0001628280-26-035067.md) | [25.2](/filings/0001628280-26-035067.md) | [38.3](/filings/0001628280-25-038860.md) | [29.6](/filings/0001001233-25-000024.md) | [20.9](/filings/0001628280-26-035067.md) | [27.6](/filings/0001628280-26-035067.md) |
| Current assets | $m | [160](/filings/0001628280-23-028200.md) | [148](/filings/0001628280-23-035989.md) | [94.3](/filings/0001628280-25-013088.md) | [68.6](/filings/0001628280-24-022194.md) | [40.1](/filings/0001628280-24-035165.md) | [58.1](/filings/0001628280-24-047102.md) | [51.7](/filings/0001628280-26-022029.md) | [37.6](/filings/0001628280-25-024650.md) | [49.9](/filings/0001628280-25-038860.md) | [44.1](/filings/0001001233-25-000024.md) | [35.8](/filings/0001628280-26-035067.md) | [37.1](/filings/0001628280-26-035067.md) |
| Total assets | $m | [325](/filings/0001628280-23-028200.md) | [220](/filings/0001628280-23-035989.md) | [165](/filings/0001628280-25-013088.md) | [129](/filings/0001628280-24-022194.md) | [93.0](/filings/0001628280-24-035165.md) | [111](/filings/0001628280-24-047102.md) | [102](/filings/0001628280-26-022029.md) | [86.2](/filings/0001628280-25-024650.md) | [97.6](/filings/0001628280-25-038860.md) | [88.6](/filings/0001001233-25-000024.md) | [59.7](/filings/0001628280-26-035067.md) | [60.0](/filings/0001628280-26-035067.md) |
| Current liabilities | $m | [53.8](/filings/0001628280-23-028200.md) | [48.5](/filings/0001628280-23-035989.md) | [47.7](/filings/0001628280-25-013088.md) | [40.2](/filings/0001628280-24-022194.md) | [39.0](/filings/0001628280-24-035165.md) | [43.2](/filings/0001628280-24-047102.md) | [45.8](/filings/0001628280-26-022029.md) | [49.6](/filings/0001628280-25-024650.md) | [47.7](/filings/0001628280-25-038860.md) | [50.1](/filings/0001001233-25-000024.md) | [42.5](/filings/0001628280-26-035067.md) | [53.1](/filings/0001628280-26-035067.md) |
| Total liabilities | $m | [91.4](/filings/0001628280-23-028200.md) | [84.8](/filings/0001628280-23-035989.md) | [82.4](/filings/0001628280-25-013088.md) | [72.3](/filings/0001628280-24-022194.md) | [69.3](/filings/0001628280-24-035165.md) | [72.1](/filings/0001628280-24-047102.md) | [78.9](/filings/0001628280-26-022029.md) | [81.3](/filings/0001628280-25-024650.md) | [78.0](/filings/0001628280-25-038860.md) | [82.4](/filings/0001001233-25-000024.md) | [74.0](/filings/0001628280-26-035067.md) | [78.9](/filings/0001628280-26-035067.md) |
| Shareholders' equity | $m | [234](/filings/0001628280-24-047102.md) | [135](/filings/0001628280-24-047102.md) | [82.9](/filings/0001628280-26-022029.md) | [56.7](/filings/0001628280-25-038860.md) | [23.7](/filings/0001001233-25-000024.md) | [39.1](/filings/0001001233-25-000024.md) | [22.8](/filings/0001628280-26-035067.md) | [4.9](/filings/0001628280-26-035067.md) | [19.6](/filings/0001001233-25-000024.md) | [6.2](/filings/0001001233-25-000024.md) | [(14.3)](/filings/0001628280-26-035067.md) | [(19.0)](/filings/0001628280-26-035067.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(60.7) d](/filings/0001628280-24-035165.md) | [(47.3) d](/filings/0001628280-24-047102.md) | [(50.5) d](/filings/0001628280-25-013088.md) | [(48.7)](/filings/0001628280-25-024650.md) | [(26.9) d](/filings/0001628280-25-038860.md) | [11.8 d](/filings/0001001233-25-000024.md) | [(3.4) d](/filings/0001628280-26-022029.md) | [(26.1)](/filings/0001628280-26-035067.md) | [(18.2) d](/filings/0001628280-25-038860.md) | [(28.5) d](/filings/0001001233-25-000024.md) | [(24.4) d](/filings/0001628280-26-022029.md) | [(19.3)](/filings/0001628280-26-035067.md) |
| Capital expenditure | $m | [5.5 d](/filings/0001628280-24-035165.md) | [2.7 d](/filings/0001628280-24-047102.md) | [2.7 d](/filings/0001628280-25-013088.md) | [0.0](/filings/0001628280-24-022194.md) | [0.0 d](/filings/0001628280-25-038860.md) | [0.1 d](/filings/0001001233-25-000024.md) | [0.2 d](/filings/0001628280-26-022029.md) | [0.0](/filings/0001628280-26-035067.md) | [0.0 d](/filings/0001628280-25-038860.md) | [0.1 d](/filings/0001001233-25-000024.md) | [0.0 d](/filings/0001628280-26-022029.md) | [0.0](/filings/0001628280-26-035067.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [148](/filings/0001628280-23-028200.md) | [158](/filings/0001628280-23-035989.md) | [169](/filings/0001628280-24-022194.md) | [174](/filings/0001628280-24-035165.md) | [177](/filings/0001628280-24-047102.md) | [180](/filings/0001628280-25-024650.md) | [204](/filings/0001628280-25-038860.md) | [214](/filings/0001001233-25-000024.md) | [220](/filings/0001628280-26-035067.md) | [257](/filings/0001628280-25-038860.md) | [304](/filings/0001001233-25-000024.md) | [390](/filings/0001628280-26-035067.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 414,288,847 at 2026-05-11, from the cover of the [10-Q filed 2026-05-14](/filings/0001628280-26-035067.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.